KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Teladoc Health (TDOC) EBITDA (2016 - 2026)

Teladoc Health's EBITDA history spans 13 years, with the latest figure at -$64.5 million for Q1 2026.

  • On a quarterly basis, EBITDA rose 29.76% to -$64.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$169.3 million, a 83.25% increase, with the full-year FY2025 number at -$196.7 million, up 80.39% from a year prior.
  • EBITDA hit -$64.5 million in Q1 2026 for Teladoc Health, down from -$25.3 million in the prior quarter.
  • Over the last five years, EBITDA for TDOC hit a ceiling of -$24.4 million in Q4 2023 and a floor of -$6.7 billion in Q1 2022.
  • Historically, EBITDA has averaged -$892.6 million across 5 years, with a median of -$64.5 million in 2026.
  • Biggest five-year swings in EBITDA: plummeted 23469.1% in 2022 and later surged 99.36% in 2023.
  • Tracing TDOC's EBITDA over 5 years: stood at -$3.8 billion in 2022, then surged by 99.36% to -$24.4 million in 2023, then crashed by 103.99% to -$49.7 million in 2024, then surged by 49.16% to -$25.3 million in 2025, then tumbled by 155.43% to -$64.5 million in 2026.
  • Business Quant data shows EBITDA for TDOC at -$64.5 million in Q1 2026, -$25.3 million in Q4 2025, and -$48.7 million in Q3 2025.